American Tower Corp. (AMT) 10-K Red Flags
Risk signals extracted deterministically from American Tower Corp.’s SEC 10-K/10-Q XBRL filings — no LLM, every finding cites the underlying data.
Detected red flags (10)
- Receivables outpacing revenue: Accounts receivable grew +20.4% YoY vs revenue growth of +5.1%. The +15.3% spread suggests extended credit terms, channel stuffing risk, or collection deterioration. Investigate the allowance for doubtful accounts and DSO trend.
- Operating cash flow exceeds net income: OCF is 2.08x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
- Endogenous analysis: Revenue grew +5.1% but receivables grew +20.4% — the receivables-to-revenue gap suggests growth may be partially driven by extended credit terms rather than genuine demand. If DSO continues to rise, a revenue reversal or bad-debt charge could follow.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- Market cap $80.29B at $172.33 per share.
- Trailing P/E 31.91, P/S 7.54, P/B 22.79.
- Price $172.33 — downtrend (below 200-DMA); 1-month momentum positive.
- RSI(14) 39.66.
- Composite risk: Elevated.
- Leverage debt/equity 11.04 (high).
Filings & ownership
- Latest annual report (10-K) filed Feb 24, 2026.
- Latest quarterly report (10-Q) filed Jul 28, 2026.
- 30 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference American Tower Corp.; broad institutional reporting.
- Recent filers include THURSTON, SPRINGER, MILLER, HERD & TITAK, INC., Foresight Group Ltd Liability Partnership, Allen Investment Management LLC.
- 20 recent 13G passive institutional ownership notices.
Full AMT analyst report
Valuation (DCF & Graham), technicals, macro exposure, risk scorecard and 13F/13D ownership.
View full report →Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.